No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.
IMMvention retained rights to use its technology to potentially pursue other targets, such as Parkinson’s or Alzheimer’s ...
Just because Wall Street likes a stock doesn't mean it's a great pick. However, it's not a bad idea to at least consider how ...
A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.
The city of Greensboro has joined a national litigation campaign suing the nation's three largest pharmacy benefit managers and three largest insulin manufacturers with the goal of lowering insulin pr ...
Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...
IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback